Association between intravitreal anti-vascular endothelial growth factor agents and hypertension: a meta-analysis
This meta-analysis found no significant difference in hypertension risk between different intravitreal anti-VEGF agents or sham injection. These results reinforce the notion that these agents have similar and safe side effect profiles, and that the choice of agent should not be based on the risk of hypertension.
Authors
- Ahmed Kamel Abdel Aal (ORCID: https://orcid.org/0000-0003-3170-6180)
- Aaditeya Jhaveri (ORCID: https://orcid.org/0000-0003-1215-072X)
- Peter J. Kertes (ORCID: https://orcid.org/0000-0002-0348-5096)
- Marko M. Popovic (ORCID: https://orcid.org/0000-0002-0370-5968)
- Rajeev H. Muni (ORCID: https://orcid.org/0000-0003-0465-6472)
- Michael Balas (ORCID: https://orcid.org/0000-0002-5948-0331)
- Faran Khalid
Institutions
- St. Michael's Hospital (CA)
- Dalhousie University (CA)
- Sunnybrook Health Science Centre (CA)
- University of Toronto (CA)
- McMaster University (CA)
Publication Details
- Journal
- Canadian Journal of Ophthalmology
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1016/j.jcjo.2025.05.014
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00